Table 2.
Factors associated with overall survival
| Characteristics | N | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | Adjusted HR | 95% CI | P | ||
| Age, years | |||||||
| <50 | 39 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| ≥50 | 89 | 2.848 | 0.825−9.835 | 0.098 | 2.407 | 0.668−8.670 | 0.179 |
| FIGO stage | |||||||
| III | 77 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| IV | 51 | 2.055 | 0.734−5.753 | 0.170 | 1.248 | 0.434−3.591 | 0.682 |
| Primary treatment strategy | |||||||
| PDS | 79 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| NAC | 49 | 3.790 | 1.483−9.691 | 0.005 | 4.098 | 1.478−11.359 | 0.007 |
| Residual tumor after PDS/IDS | |||||||
| Optimal debulking | 109 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| Suboptimal debulking | 19 | 1.723 | 0.545−5.442 | 0.354 | 1.935 | 0.559−6.703 | 0.298 |
| BRCA status | |||||||
| Wild-type | 77 | 1 (Ref) | − | − | 1 (Ref) | − | − |
| Mutation | 51 | 0.584 | 0.228−1.495 | 0.262 | 0.768 | 0.283−2.082 | 0.603 |
Abbreviations: CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC neoadjuvant chemotherapy, IDS interval debulking surgery, HR hazard ratio, CI confidence interval, Ref reference